ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Karyopharm Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 5.77% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -4.72
2
Flat results in Jun 25
- INTEREST(HY) At USD 22.22 MM has Grown at 49.81%
- CASH AND EQV(HY) Lowest at USD 121.64 MM
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.25 times
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -56.75%, its profits have risen by 26.8%
4
Below par performance in long term as well as near term
- Along with generating -56.75% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Karyopharm Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Karyopharm Therapeutics, Inc.
-51.36%
-0.04
1635.03%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.61%
EBIT Growth (5y)
5.77%
EBIT to Interest (avg)
-4.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
11.30
Tax Ratio
0.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.36%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.19
EV to EBIT
-1.25
EV to EBITDA
-1.26
EV to Capital Employed
-1.56
EV to Sales
1.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at USD -60.71 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -58.14 %
RAW MATERIAL COST(Y)
Fallen by -0.69% (YoY
OPERATING PROFIT(Q)
Highest at USD -24.31 MM
OPERATING PROFIT MARGIN(Q)
Highest at -64.09 %
-15What is not working for the Company
INTEREST(HY)
At USD 22.22 MM has Grown at 49.81%
CASH AND EQV(HY)
Lowest at USD 121.64 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.25 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.87 times
PRE-TAX PROFIT(Q)
Lowest at USD -37.21 MM
NET PROFIT(Q)
Lowest at USD -37.25 MM
EPS(Q)
Lowest at USD -4.32
Here's what is working for Karyopharm Therapeutics, Inc.
Debt-Equity Ratio
Lowest at -58.14 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Profit
Highest at USD -24.31 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -64.09 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Raw Material Cost
Fallen by -0.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Karyopharm Therapeutics, Inc.
Pre-Tax Profit
At USD -37.21 MM has Fallen at -38.85%
over average net sales of the previous four periods of USD -26.8 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -37.25 MM has Fallen at -39.13%
over average net sales of the previous four periods of USD -26.77 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Interest
At USD 22.22 MM has Grown at 49.81%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Pre-Tax Profit
Lowest at USD -37.21 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -37.25 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD -4.32
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Cash and Eqv
Lowest at USD 121.64 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Inventory Turnover Ratio
Lowest at 1.25 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.87 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
